Previous 10 | Next 10 |
2023-04-06 05:40:50 ET Singapore's Health Sciences Authority (HSA) accepted to review Everest Medicines' application seeking approval of Nefecon to treat primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. The company expects to get approval of the...
Calliditas to participate in upcoming investor conferences PR Newswire STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following i...
2023-03-13 13:15:19 ET Calliditas Therapeutics ( NASDAQ: CALT ) added 35% on Monday after announcing that its Phase 3 trial for renal disease candidate Nefecon reached the primary endpoint, paving the way for Swedish pharma to seek its full approval. In Dec. 2021, the U....
2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...
2023-03-13 10:02:38 ET Gainers: Provention Bio PRVB +248% . Caleminder ( CMND ) +38% . Calliditas Therapeutics ( CALT ) +32% . Euda Health ( EUDA ) +22% . Seagen ( SGEN ) +15% . Losers: Cingulate CING -28...
2023-03-13 08:54:26 ET Provention Bio PRVB +263% on ~$2.9B acquisition by Sanofi. Calliditas Therapeutics ( CALT ) +29% announces primary endpoint successfully Met in phase 3 NefIgArd trial evaluating Nefecon® in IgA Nephropathy. Caleminder ( CMND ...
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy PR Newswire STOCKHOLM , March 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Callidi...
Summary Calliditas Therapeutics is a commercial-stage biopharmaceutical company based in Sweden focused on developing and commercializing novel treatments for rare diseases. TARPEYO is the only disease-modifying therapy approved for IgAN. We expect TARPEYO's 2023 sales to be better ...
Calliditas Therapeutics press release ( NASDAQ: CALT ): Q4 GAAP loss of -SEK0.07 Revenue of SEK429M vs. SEK31.2M in 4Q21. For further details see: Calliditas Therapeutics reports Q4 results
Calliditas - Year-End Report, 2022 PR Newswire 2022: Successful transformation into a commercial stage company STOCKHOLM , Feb. 23, 2023 /PRNewswire/ -- "2022 was a fantastic year for Calliditas as we launched TARPEYO ® in the US, the first a...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...